Chapter 7

The Pharma–Doctor Nexus

Dr. Devashish Bharadwaj
MD-CHA Resident, NIHFW

Introduction: A Relationship Too Close for Comfort

In an ideal world, the doctor–pharmaceutical relationship is grounded in **science, ethics, and patient welfare**. In India, it has increasingly evolved into a relationship of **mutual convenience, opaque financial incentives, and conflicted interests**.

Pharmaceutical companies invest massive resources to "win" doctors. In return, they expect—and often receive—**prescription loyalty**. This nexus affects everything from **drug choice and dosage** to **diagnostic referrals and surgery timing**.

This chapter uncovers the anatomy of the pharma–doctor relationship, its incentives, grey zones, and impacts on patients and policy.

1. Anatomy of the Nexus

The pharma–doctor nexus operates at multiple levels:

| Table 1: Interaction Channels Between Pharma & Doctors |

Channel	Typical Benefit to Doctor	Hidden Cost to Patient
Sales rep visits	Free samples, gifts	Prescription bias
Sponsored CMEs	Paid travel, stay, fees	Inflated drug costs
Clinical trials	Honoraria, consulting deals	Biased reporting or recruitment
Brand promotion	Volume-linked rewards	Overuse of costly brands
Hospital panels	Cutbacks for brand exclusives	Limited brand choices

Source: Adapted from PHFI Ethics Audit 2021 [1]

While **industry-doctor interaction is essential for scientific exchange**, the **absence of transparency and oversight** in India makes it **vulnerable to abuse**.

2. Sponsored Conferences: Science or Sales Trips?

Continuing Medical Education (CME) is legally required for doctors to maintain licensing. However, in India:

- **CME events are often fully funded by pharmaceutical firms**
- Destinations include **Bali, Dubai, Paris, and Singapore**
- Often organized around festivals or long weekends

A 2019 study found that **71% of conferences attended by Indian doctors were sponsored by pharma firms**, with **no independent academic oversight** [2].

"What looks like a CME is often just a marketing show wrapped in scientific jargon." – Ex-IMA official, Mumbai

Doctors who regularly attend such events often **prescribe the host company's brands disproportionately**, reinforcing **commercial dependency**.

3. Gifts, Honoraria, and Shadow Payments

Though technically banned by the UCPMP (Uniform Code for Pharmaceutical Marketing Practices), **indirect payments to doctors continue** under euphemisms such as:

- "Speaker honorarium"
- "Clinical advisory board fees"
- "Consulting services"
- "Product feedback surveys"

| Table 2: Common Pharma Payments to Doctors (2018–2023) |

Payment Type	Estimated Annual Value (India)
Sponsored travel/CME	?3,500 crore
Honoraria and consulting	?1,200 crore
Gifts and incentives	?1,000 crore

Source: Transparency International India, 2023 [3]

In many cases, doctors are given **volume targets**—prescribe a certain number of strips or injections monthly—and **incentives escalate** with performance.

4. Hospital Panels and Internal Bias

In corporate hospital chains, doctors are often **mandated to prescribe from select brand panels** chosen through internal procurement deals.

- These panels are **not always based on cost or efficacy**
- Pharma companies **offer discounts, sponsorships, or infrastructure support** to hospitals for exclusivity
- Doctors **face pressure** to maintain prescription volume for preferred brands

In some hospitals, **consultants receive a share of pharma-linked diagnostics, implants, or drug use**, institutionalizing the **nexus within hospital infrastructure** [4].

5. Clinical Trials: Science or Strategy?

Indian doctors are increasingly involved in clinical trials sponsored by pharmaceutical companies. While legitimate trials are essential, problems emerge when:

- Doctors recruit patients without informed consent
- Trial data is ghostwritten or selectively reported
- Trials are used to build loyalty rather than generate science

A 2020 report by the **WHO South-East Asia office** found that **40% of Indian trial sites lacked independent ethics oversight**, and 22% had **serious documentation gaps** [5].

"For many physicians, a clinical trial becomes just another income stream—not a scientific duty." – Medical ethicist, Delhi.

6. Referral Commissions and Kickbacks

Another arm of the nexus involves **cross-specialty referrals** and **kickbacks**:

- Surgeons referring to diagnostic centers for a fee
- Physicians recommending specialist consultations with mutual referral agreements

• Commissions on expensive biologics, implants, or chemotherapy drugs

Though illegal under the **Indian Medical Council Regulations (2002)** and NMC guidelines, **enforcement is nearly absent**.

| Table 3: Referral Commission Range in Urban Areas |

Service Referred	Commission Estimate (%)
MRI/CT Scan	20–30%
High-end blood panels	15–20%
Private hospitalization	?2,000–?5,000 per case
Cancer drug infusions	?500–?2,000 per dose

Source: Medico Legal Review Journal, 2021 [6]

7. Regulatory and Ethical Frameworks: Weak Links

Despite the existence of ethical codes, enforcement remains minimal:

- **UCPMP** is **voluntary and lacks legal backing**
- **National Medical Commission (NMC)** guidelines are **non-binding** unless pursued through a complaint
- **CDSCO** regulates drugs, not doctor conduct
- **Hospitals** are rarely audited for pharma affiliations

Only **18 disciplinary actions** have been taken against doctors for pharma-related violations between 2015–2022 [7].

8. International Comparisons: India Is Behind

| Table 4: Regulation of Pharma–Doctor Financial Ties |

Country	Mandatory Payment Disclosure	Annual Public Registry	Enforcement Fines
USA	Yes (Sunshine Act)	Yes	Yes (up to $1M)
France	Yes	Yes	Yes
UK	Partial	Yes (Voluntary)	Moderate
India	No	No	No

Source: WHO Global Pharma Ethics Survey, 2022 [8]

India lacks a **Sunshine Law** requiring disclosure of doctor–industry financial ties, creating an opaque environment where **public trust erodes rapidly**.

9. Patient Perception: Rising Distrust

Patients are increasingly suspicious of prescriptions, particularly when:

- Doctors **push expensive brands without alternatives**
- Prescriptions change monthly without justification
- Investigations or imaging seem excessive

A 2021 survey by **Jan Swasthya Abhiyan** found that **61% of Indian patients believed doctors were "influenced by drug companies"**, and **58% said they never understood why one brand was prescribed over another** [9].

"I trust my doctor—but I don't trust what's written on the prescription." – Patient, Pune

10. Reimagining the Relationship: Reform Pathways

| Table 5: Reform Suggestions for Doctor–Pharma Ethics |

Reform Proposal	Feasibility / Status
Legalise UCPMP	Pending (under MoHFW review)
Create Doctor–Pharma Payment Registry	Not yet initiated
Ban pharma sponsorship of CMEs	Opposed by IMA
Government-funded CME platform	Pilot underway (NMC)
Mandatory disclosure on prescriptions	Under consideration

Other proposals include:

- Linking prescription audits to doctor re-certification
- Creating **ethics ombudsmen** at state medical councils
- Encouraging **public awareness of drug options**

Conclusion: When Care Becomes Commerce

The relationship between doctors and pharmaceutical companies is supposed to advance science, not sales. Yet in India, **commercial loyalty too often trumps medical logic**, and patient welfare becomes a casualty.

Until there is **transparency in payments**, **binding ethical oversight**, and **legal deterrents for abuse**, this nexus will continue to undermine trust—not only in individual doctors, but in the entire healthcare system.

References

1. Public Health Foundation of India. Ethical Practices in India's Drug Promotion. 2021.
2. Indian Journal of Medical Ethics. Pharma-Funded CME in India: A Growing Ethical Problem. 2019.
3. Transparency International India. Pharma Expenditure Report: 2023.
4. Economic & Political Weekly. Pharma Incentives and Corporate Hospitals. 2022.
5. WHO-SEARO. Clinical Trials Oversight in India. Regional Office Report, 2020.
6. Medico Legal Review. Referral Commissions in Indian Private Healthcare. 2021.
7. National Medical Commission. Disciplinary Action Database. 2015–2022.
8. WHO. Global Health Ethics Report: Physician–Industry Relations. 2022.
9. Jan Swasthya Abhiyan. Patient Trust and Transparency Survey. 2021.